Long-term results of two unconventional agents in steroid-dependent nephrotic children

Area of Science:

• Pediatric Nephrology
• Clinical Pharmacology

Background:

• Steroid-dependent minimal change nephrotic syndrome (MCNS) in children often leads to significant steroid-related adverse events.
• Alternative immunosuppressive therapies, including oral cyclophosphamide, carry their own risks of severe side effects.

Purpose of the Study:

• To prospectively compare the long-term efficacy and safety of levamisole versus intravenous (IV) pulse cyclophosphamide in children with idiopathic steroid-dependent MCNS.
• To identify a treatment with potentially fewer adverse effects for this vulnerable pediatric population.

Main Methods:

• A randomized prospective study involving 40 children (age 3-15 years) with steroid-dependent MCNS.
• Patients were assigned to receive either levamisole (2.5 mg/kg on alternate days) or IV pulse cyclophosphamide (500 mg/m²/month for six months).
• Prednisolone was gradually tapered off during treatment, and remission rates were assessed over four years.

Main Results:

• Both levamisole and IV cyclophosphamide showed similar remission maintenance rates at various follow-up points (e.g., 25% in each group at six months, 15% vs. 5% at two years).
• The overall incidence of side effects was mild in both treatment groups.
• Both levamisole and IV cyclophosphamide were generally well-tolerated by the pediatric patients.

Conclusions:

• Levamisole appears to be a viable therapeutic option for children with steroid-dependent MCNS, demonstrating comparable efficacy to IV cyclophosphamide.
• Given its milder side effect profile, levamisole is recommended as a preferred initial alternative therapy before considering treatments with more significant adverse event risks.